<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01136525</url>
  </required_header>
  <id_info>
    <org_study_id>07-VIN-027</org_study_id>
    <nct_id>NCT01136525</nct_id>
  </id_info>
  <brief_title>Bioavailability Study of Valacyclovir HCl Tablets, 1000 mg of Dr. Reddy's Under Fasting Conditions</brief_title>
  <official_title>An Open Label, Balanced, Randomized, Two Treatment, Two-sequence, Two-period, Single-dose Crossover Comparative Bioavailability Study of 1000 mg Valacyclovir HCl Tablets of Dr. Reddys's and Valtrex (R) 1 gm Caplets of GlaxoSmithkline in Healthy Volunteers Under Fasting Conditions.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Reddy's Laboratories Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Reddy's Laboratories Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to

        1. Compare and evaluate the single-dose bioavailability study of 1000mg Valacyclovir HCl
           tablets of Dr. Reddy's and Valtrex (R)(Valacyclovir Hydrochloride)CAPLETS 1 gram of
           GlaxoSmithkline, in healthy, adult human subjects under fasting conditions.

        2. monitor the adverse events and ensure the safety of subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An open label, balanced, randomized, two-treatment, two-sequence two-period, single-dose,
      crossover comparative bioavailability study of 1000 mg Valacyclovir Hydrochloride Tablets of
      Dr. Reddy's Laboratories Ltd., India and valtrex (R) (Valacyclovir Hydrochloride) CAPLETS 1
      gram of GlaxoSmithkline in healthy, adult human subjects under fasting conditions
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">May 2007</completion_date>
  <primary_completion_date type="Actual">March 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioequivalence based on Cmax and AUC parameters</measure>
    <time_frame>4 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Valacyclovir Hydrochloride</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Valacyclovir Hydrochloride Tablets, 1000 mg of Dr. Reddy's Laboratories Limited</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Valtrex (R)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Valtrex (R) (Valacyclovir Hydrochloride) CAPLETS 1 gram of GlaxoSmithkline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valacyclovir Hydrochloride</intervention_name>
    <description>Valacyclovir Hydrochloride Tablets, 1000 mg of Dr. Reddy's Laboratories Limited</description>
    <arm_group_label>Valacyclovir Hydrochloride</arm_group_label>
    <arm_group_label>Valtrex (R)</arm_group_label>
    <other_name>Valtrex (R)(Valacyclovir Hydrochloride) CAPLETS 1 gm</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        The subjects were selected for study participation, based on the following criteria:

          1. Human subjects aged between 18 and 45 years (including both).

          2. Subjects' weight within the normal range according to normal values for the Body Mass
             Index (18.5 to 24.9 kg/m2) with minimum of 50 kg weight.

          3. Subjects with normal health as determined by personal medical history, clinical
             examination and laboratory examinations within the clinically acceptable normal range.

          4. Subjects having normal 12-lead electrocardiogram (ECG).

          5. Subjects having normal chest X-Ray (PIA view).

          6. Have a negative urine screen for drugs of abuse (including amphetamines, barbiturates,
             benzodiazepines, marijuana, cocaine, and morphine).

          7. Have negative alcohol breath test.

          8. Subjects willing to adhere to the protocol requirements and to provide written
             informed consent.

        Exclusion Criteria:

        The subjects were excluded from the study, based on the following criteria:

          1. Hypersensitivity to Valacyclovir Hydrochloride or related drugs.

          2. History or presence of significant cardiovascular, pulmonary, hepatic, renal,
             gastrointestinal, endocrine, immunological, dermatological, neurological or
             psychiatric disease or disorder.

          3. History or presence of significant alcoholism or drug abuse in the past one year.

          4. History or presence of significant smoking (more than 10 cigarettes or beedi' s/day).

          5. History or presence of significant asthma, urticaria or other allergic reactions.

          6. History or presence of significant gastric and/or duodenal ulceration.

          7. History or presence of significant thyroid disease, adrenal dysfunction, organic
             intracranial lesion such as pituitary tumour.

          8. History or presence of cancer.

          9. Difficulty with donating blood.

         10. Difficulty in swallowing solids like tablets or capsules.

         11. Systolic blood pressure less than 100 mm Hg or more than 140 mm Hg.

         12. Diastolic blood pressure less than 60 mm Hg or more than 90 mm Hg.

         13. Pulse rate less than 50/minute or more than 100/minute.

         14. Oral temperature less than 95°F or more than 98.6°F.

         15. Respiratory rate less than 12/minute or more than 20/minute

         16. Subjects who have used any prescription medication, within 14 days of period 01 dosing
             or OTC medication within 14 days of period 01 dosing.

         17. Major illness during 3 months before screening.

         18. Participation in a drug research study within past 3 months.

         19. Donation of blood in the past 3 months before screening.

         20. Subjects who have consumed xanthine-containing products (including caffeine,
             theobromines, etc.) within 48 hours prior to period 01 dosing.

         21. Subjects who have consumed food or beverages containing grapefruit or pomelo within 14
             days prior to period 01 dosing.

         22. Subjects who have used any drugs or substances known to be strong inhibitors of CYP
             enzymes (formerly known as cytochrome P450 enzymes) within 28 days prior to the first
             dose.

         23. Subjects who have used any drugs or substances known to be strong inducers of CYP
             enzymes (formerly known as cytochrome P450 enzymes) within 28 days prior to the first
             dose.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. Dharmesh Domadia, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Veeda clinical research Pvt. Ltd., India</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Veeda clinical research Pvt. Ltd., India</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujrat</state>
        <zip>380 015</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>June 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 2, 2010</study_first_submitted>
  <study_first_submitted_qc>June 2, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2010</study_first_posted>
  <last_update_submitted>June 11, 2010</last_update_submitted>
  <last_update_submitted_qc>June 11, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 14, 2010</last_update_posted>
  <responsible_party>
    <name_title>Mr. Indu Bhushan/Senior Director</name_title>
    <organization>Dr. Reddy's Laboratories Limited</organization>
  </responsible_party>
  <keyword>Bioequivalence</keyword>
  <keyword>Crossover</keyword>
  <keyword>Valacyclovir Hydrochloride</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valacyclovir</mesh_term>
    <mesh_term>Acyclovir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

